FDA approves Novartis' Signifor drug for rare hormonal disorder

Reuters: U.S. health regulators have approved Novartis' drug Signifor LAR as a treatment for a rare and life-threatening hormonal disorder, the Swiss drugmaker said on Tuesday.

The Basel-based firm said the U.S. Food and Drug Administration (FDA) backed its drug Signifor LAR to treat acromegaly in adults for whom surgery is not an option, after two late-stage studies showed the drug allowed for greater disease control than existing therapies.

Read article